ResearcherGerman Cancer Research CenterNo recent work listed
Hassan Adwan
Matched on OpenAlex author ID A5026492117. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper
Papers 5
- The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis. Last author DOI 10.3892/ol.2017.7526↗
- Metastasis-related processes show various degrees of activation in different stages of pancreatic cancer rat liver metastasis. Last author DOI 10.1159/000365496↗
- Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. Co-author DOI 10.4161/cbt.29503↗
- Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats. Last author DOI 10.3892/or.2012.2049↗
- Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2011.217↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Martin Reinhold Berger · 5 shared papers, 2011–2018 · strength 0.27
- Paper The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metast… DOI 10.3892/ol.2017.7526↗
- Paper Metastasis-related processes show various degrees of activation in different stages of pancreatic cancer rat liver meta… DOI 10.1159/000365496↗
- Paper Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. DOI 10.4161/cbt.29503↗
- Ahmed Murtaja · 2 shared papers, 2014–2018 · strength 0.16
- Khamael K. Al-Taee · 2 shared papers, 2014 · strength 0.11
- Ergül Eyol · 2 shared papers, 2011–2012 · strength 0.06
- Jorg H. Kleeff · 2 shared papers, 2011–2012 · strength 0.06
- Helmut Frieß · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.